Impact of the New EU HTA Regulation on Access to Innovative Medicines in Europe
Access to innovative medicines in Europe continues to be one of the major pending issues, especially considering the significant differences observed between countries. In recent years, the EU has developed a series of regulations that impact access. One of the most significant is the European Union Health Technology Assessment Regulation (EU HTA), aimed at addressing uneven access across the EU, among other goals.
This new regulation will entail important changes for innovative companies. As part of #BIOSPAIN2023Interview initiative, Chus Castillo, Partner Consulting Iberia at Alira Health, spoke about the “Impact of the New EU HTA Regulation on Access to Innovative Medicines in Europe.”
Read Chus’ interview on AseBio’s website to get the latest updates on the HTA Regulation, related challenges, and its potential effect on access to innovative medicines.